Exelixis Inc EXEL:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 12:05 PM EDT
18.30quote price arrow up+0.11 (+0.60%)
Volume
563,102
52 week range
15.50 - 23.52
Loading...
  • Open18.22
  • Day High18.52
  • Day Low18.00
  • Prev Close18.19
  • 52 Week High23.52
  • 52 Week High Date06/25/21
  • 52 Week Low15.50
  • 52 Week Low Date12/06/21

Key Stats

  • Market Cap5.87B
  • Shares Out320.74M
  • 10 Day Average Volume4.53M
  • Dividend-
  • Dividend Yield-
  • Beta0.78
  • YTD % Change0.05

KEY STATS

  • Open18.22
  • Day High18.52
  • Day Low18.00
  • Prev Close18.19
  • 52 Week High23.52
  • 52 Week High Date06/25/21
  • 52 Week Low15.50
  • 52 Week Low Date12/06/21
  • Market Cap5.87B
  • Shares Out320.74M
  • 10 Day Average Volume4.53M
  • Dividend-
  • Dividend Yield-
  • Beta0.78
  • YTD % Change0.05

RATIOS/PROFITABILITY

  • EPS (TTM)0.92
  • P/E (TTM)19.83
  • Fwd P/E (NTM)22.26
  • EBITDA (TTM)389.409M
  • ROE (TTM)14.18%
  • Revenue (TTM)1.521B
  • Gross Margin (TTM)96.52%
  • Net Margin (TTM)19.60%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/03/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Exelixis Inc

There is no recent news for this security.

Profile

MORE
Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for...
Stelios Papadopoulos Ph.D.
Independent Chairman of the Board, Co-Founder
Michael Morrissey Ph.D.
President, Chief Executive Officer, Director
Christopher Senner CPA
Chief Financial Officer, Executive Vice President
Patrick Haley
Executive Vice President - Commercial
Jeffrey Hessekiel J.D.
Executive Vice President, General Counsel, Secretary
Address
1851 Harbor Bay Pkwy
Alameda, CA
94502-3016
United States

Top Peers

SYMBOLLASTCHG%CHG
NVAX
Novavax Inc
53.59+6.52+13.85%
MEDP
Medpace Holdings Inc
146.42+10.88+8.03%
SRPT
Sarepta Therapeutics Inc
74.51+3.61+5.09%
CRSP
CRISPR Therapeutics AG
57.31+2.08+3.77%
NBIX
Neurocrine Biosciences Inc
92.05+2.21+2.46%